Since its approval in 2011 for patients with recurrent glioblastoma (GBM), physicians have responded positively to the non-invasive nature of the NovoTTF-100A System device (NovoCure Ltd, Haifa, Israel), citing significantly less toxicity and a better quality of life profile compared to available conventional therapies. A roundtable discussion (available at: http://education.seminoncol.org /path.php?1399:0:Media:title:bxvcs) was recently convened to provide a knowledge-based perspective surrounding current treatment options for patients with GBM and the clinical challenges involved with the treatment of recurrent GBM patients who have failed prior therapies. The participating roundtable experts discussed the challenges encountered in managing GBM patients, the current approved treatment options for these patients, the efficacy and safety profile of NovoTTF therapy (TTFields), and its use as a novel treatment modality for recurrent GBM patients.
